Adjunctive and Supportive Measures for Community-Acquired Pneumonia

  • Grant W. Waterer
  • Richard G. Wunderink


The widespread introduction of penicillin in the 1940s resulted in a substantial reduction in mortality from community-acquired pneumonia (CAP). However, despite significant advances in medical science, only a small improvement has occurred since, particularly in patients with bacteremic pneumococcal pneumonia [1, 2]. Even modern intensive care has only made a small difference to the mortality in patients with severe pneumonia [3, 4]. While the aging population, increased number of patients with severe co-morbid illnesses, and the human immunodeficiency virus (HIV) epidemic have certainly contributed to the persistently high mortality rate [2, 5, 6], apparently healthy, immunocompetent patients continue to die from CAP.


Septic Shock Acute Respiratory Distress Syndrome Respir Crit Extracorporeal Membrane Oxygenation Severe Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors and prognosis. Rev Infect Dis 7:133, 1985.PubMedCrossRefGoogle Scholar
  2. 2.
    Watankunakorn C, Bailey TA. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992–1996. Arch Intern Med 157:1965, 1997.CrossRefGoogle Scholar
  3. 3.
    Hook EW, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 249:1055, 1983.PubMedCrossRefGoogle Scholar
  4. 4.
    Franklin C, Henrickson K, Weil MH. Reduced mortality of pneumococcal bacteremia after early intensive care. J Intensive Care Med 6:302, 1991.Google Scholar
  5. 5.
    Torres JM, Cardenas O, Vasquez A, Schlossberg D. Streptococcus pneumoniae bacteremia in a community hospital. Chest 113:387, 1998.PubMedCrossRefGoogle Scholar
  6. 6.
    Plouffe JF, Breiman RF, Facklam RR, Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. JAMA 275:194, 1996.PubMedCrossRefGoogle Scholar
  7. 7.
    Waterer GW, Quasney MW, Zhang Q, Jones CB, Wunderink RG. The impact of the TNFb + 250 gene polymorphism on the severity of community-acquired pneumonia. Chest 116:265S Abstract, 1999.Google Scholar
  8. 8.
    Westendorp RGJ, Langermans JAM, Huizinga TWJ, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170, 1997.PubMedCrossRefGoogle Scholar
  9. 9.
    Gagnon S, Ahmad M, Boota ND, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 323:1444, 1990.PubMedCrossRefGoogle Scholar
  10. 10.
    Bozette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 323:1451, 1990.CrossRefGoogle Scholar
  11. 11.
    Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest 114:426, 1998.PubMedCrossRefGoogle Scholar
  12. 12.
    Goldman M, Johnson PC, Sarosi GA. Fungal pneumonias. The endemic mycoses. Clin Chest Med 20:507, 1990.CrossRefGoogle Scholar
  13. 13.
    Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 22:S102, 1996.PubMedCrossRefGoogle Scholar
  14. 14.
    Tognian S, Jiayu Y, Liye Z, Weiwu D, Zhaoying S. Chemotherapy and its combination with corticosteroids in acute miliary tuberculosis in adolescents and adults: analysis of 55 cases. Chin Med J 94:309, 1981.Google Scholar
  15. 15.
    Lebel MH, Freij BJ. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo controlled trials. N Engl J Med 319:964, 1988.PubMedCrossRefGoogle Scholar
  16. 16.
    Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. Chest 104:389, 1993.PubMedCrossRefGoogle Scholar
  17. 17.
    Klugman K. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 3:171, 1990.PubMedGoogle Scholar
  18. 18.
    Torres A, Ewig S, El-Ebiary M, Filella X, Xaubet A. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur RespJ 14:218, 1999.CrossRefGoogle Scholar
  19. 19.
    Casey LC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771, 1993.PubMedCrossRefGoogle Scholar
  20. 20.
    Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest 107:1342, 1995.PubMedCrossRefGoogle Scholar
  21. 21.
    van Dissel JT. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351:950, 1998.PubMedCrossRefGoogle Scholar
  22. 22.
    Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MAD, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 12:1439, 1995.Google Scholar
  23. 23.
    Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert E, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26:645, 1998.PubMedCrossRefGoogle Scholar
  24. 24.
    Reinhart K, Wiegand-Lönhart C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multi-center, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733, 1996.PubMedCrossRefGoogle Scholar
  25. 25.
    Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273:934, 1995.PubMedCrossRefGoogle Scholar
  26. 26.
    Cohen J, Carlet J, INTERSEPT: an international, multi-center, placebo-controled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med 24:1431, 1996.PubMedCrossRefGoogle Scholar
  27. 27.
    Opal SM, Fisher CJ, Dhainault JF. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25:1115, 1997.PubMedCrossRefGoogle Scholar
  28. 28.
    Fisher CJ, Dhainault JF, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Phase III rhIL-l ra Sepsis Syndrome Study Group. JAMA 271:1836, 1994.PubMedCrossRefGoogle Scholar
  29. 29.
    Fisher CJJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334:1697, 1997.CrossRefGoogle Scholar
  30. 30.
    Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. Ro 45–2081 Study Group. JAMA 277:1531, 1997.PubMedCrossRefGoogle Scholar
  31. 31.
    Haupt MJ, Jastremski MS, Clemmer TP, Metz CA, Goris GB. Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. Crit Care Med 19:1339, 1991.PubMedCrossRefGoogle Scholar
  32. 32.
    Bernard GR, Reines HD, Halushka PV. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 336:912, 1997.PubMedCrossRefGoogle Scholar
  33. 33.
    Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): results of a randomized, double-blind, placebo-controlled trial. JAMA 277:482, 1997.PubMedCrossRefGoogle Scholar
  34. 34.
    Dhainault JF, Tenaillon A, Le Tulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720, 1994.Google Scholar
  35. 35.
    Dhainault JF, Tenaillon A, Hemmer M, et al. Confirming phase III clinical trial to study the efficacy of a P.A.F. antagonist, BN 52021, in reducing mortality of patients with severe gram-negative sepsis. Am J Respir Crit Care Med 151:A47, 1995.Google Scholar
  36. 36.
    Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS). Ann Intern Med 125:680, 1996.PubMedCrossRefGoogle Scholar
  37. 37.
    Light RB. Indomethacin and acetylsalicylic acid reduce intrapulmonary shunt in experimental pneumococcal pneumonia. Am Rev Respir Dis 134:520, 1986.PubMedGoogle Scholar
  38. 38.
    Hanley PJ, Roberts D, Dobson K, et al. Effect of indomethacin on arterial oxygenation in critically ill patients with severe pneumonia. Lancet 1:351, 1987.CrossRefGoogle Scholar
  39. 39.
    Bernard GR, Reines HD, Halushka RV, Higgins SB, Metz CA, Swindell BB, et al. Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Am Rev RespirDis 144:1095, 1991.CrossRefGoogle Scholar
  40. 40.
    Ferrer M, Torres A, Bauer R, Hernández C, Roca J, Rodriguez-Roisin R. Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe pneumonia: a pilot study. Chest 111:1094, 1997.PubMedCrossRefGoogle Scholar
  41. 41.
    Dowling HF, Lepper MH. The effect of antibiotics (penicillin, aureomycin, and terramycin) on the fatality rate and incidence of complications in pneumococcic pneumonia. A comparison with other methods of therapy. Am J Med Sci 222:396, 1951.PubMedCrossRefGoogle Scholar
  42. 42.
    Kohzuki T, Eguchi Y, Kato M, Irie K, Ohtsuka H, Higuchi A, et al. Protective activity of anti-exotoxin A monoclonal antibody against mice infected with toxin-producing Pseudomonas aeruginosa. J Infect Dis 167:119, 1993.PubMedCrossRefGoogle Scholar
  43. 43.
    Hector RF, Collins MS, Pennington JE. Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monocolonal antibody. J Infect Dis 160:483, 1989.PubMedCrossRefGoogle Scholar
  44. 44.
    Pennington JE, Hickey WF, Blackwood LL, et al. Active immunization with lipopoly-saccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs. J Clin Invest 68:1140, 1981.PubMedCrossRefGoogle Scholar
  45. 45.
    Saravolatz LD, Markowitz N, Collins MS, Bogdanoff D, Pennington JE. Saftey, pharmokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. J Infect Dis 167:784, 1991.Google Scholar
  46. 46.
    Greenman RL, Schein RMH, Martin MA, et al. A controlled trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097, 1991.PubMedCrossRefGoogle Scholar
  47. 47.
    Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double blind, placebo-controlled trial. N Engl J Med 324:429, 1991.PubMedCrossRefGoogle Scholar
  48. 48.
    Bates JH, Campbell GD, Barron AL, McCracken GA, Morgan PN, Moses EB, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest 101:1005, 1992.PubMedCrossRefGoogle Scholar
  49. 49.
    Blanquer J, Blanquer R, Borrás R, Nauffal D, Morales P, Menéndez R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 46:508, 1991.PubMedCrossRefGoogle Scholar
  50. 50.
    Macfarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. Lancet 2:255, 1982.PubMedCrossRefGoogle Scholar
  51. 51.
    Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 11:586, 1989.PubMedCrossRefGoogle Scholar
  52. 52.
    Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires’ disease. Risk factors for morbidity and mortality. Arch Intern Med 154:2417, 1994.PubMedCrossRefGoogle Scholar
  53. 53.
    Moldawer LL. Biology of proinflammatory cytokines and their antagonists. Crit Care Med 22:S3, 1994.PubMedGoogle Scholar
  54. 54.
    Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 333:1618, 1995.PubMedCrossRefGoogle Scholar
  55. 55.
    Musher DM. Infections caused by Streptococcus pneumonia: clinical spectrum, pathogenesis, immunity and treatment. Clin Infect Dis 14:801, 1992.PubMedCrossRefGoogle Scholar
  56. 56.
    Repine JE, Clawson CC, Goetz FC. Bactericidal function of neutrophils from patients with acute bacterial infections and from diabetes. J Infect Dis 142:869, 1980.PubMedCrossRefGoogle Scholar
  57. 57.
    Brayton RG, Stokes PE, Schwartz MS, Louria DB. Effect of alcohol and various diseases on leucocyte mobilization, phagocytosis and intracellular bacterial killing. N Engl J Med 282:123, 1970.PubMedCrossRefGoogle Scholar
  58. 58.
    Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): The first 10 years. Blood 88:1907, 1996.PubMedGoogle Scholar
  59. 59.
    Dale DC, Liles WC, Summer WR, Nelson S. Granulocyte colony-stimulating factor-role and relationships in infectious diseases. J Infect Dis 172:1061, 1995.PubMedCrossRefGoogle Scholar
  60. 60.
    Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 163:579, 1991.PubMedCrossRefGoogle Scholar
  61. 61.
    McKenna PJ, Nelson S, Anderson J. Filgastrim (rhuG-CSF) enhances ciprofloxacin uptake and bactericidal activity of human neutrophis in vitro. Am J Respir Crit Care Med 153:A535, 1996.CrossRefGoogle Scholar
  62. 62.
    Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med 21:277, 1995.PubMedCrossRefGoogle Scholar
  63. 63.
    Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 320:365, 1989.PubMedCrossRefGoogle Scholar
  64. 64.
    Sato Y, van Eeden SF, English D, Hogg JC. Bacteremic pneumococcal pneumonia: bone marrow release and pulmonary sequestration of neutrophils. Crit Care Med 26:501, 1998.PubMedCrossRefGoogle Scholar
  65. 65.
    Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C, et al. G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 159:1377, 1999.PubMedCrossRefGoogle Scholar
  66. 66.
    Bersten A, Sibbald WJ. Acute lung injury in septic shock. Crit Care Clin 5:49, 1991.Google Scholar
  67. 67.
    Repine JE, Bechler CJ. Neutrophils and adult respiratory distress syndrome: two interlocking perspectives in 1991. Am Rev Respir Dis 144:251, 1991.PubMedCrossRefGoogle Scholar
  68. 68.
    Nelson S. A question of balance. Am J Respir Crit Care Med 159:1365, 1999.PubMedCrossRefGoogle Scholar
  69. 69.
    Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE. Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survial and multisystem organ failure. Blood 86:1301, 1995.PubMedGoogle Scholar
  70. 70.
    Preheim LC, Snitily MU, Gentry MJ. Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J Infect Dis 174:225, 1996.PubMedCrossRefGoogle Scholar
  71. 71.
    de Boisblanc BP, Summer WR, Mason C, Shellito J, Logan E, Bear M, et al. Phase 1 trial of granulocyte-colony stimulating factor in severe community acquired pneumonia. Am J Respir Crit Care Med A204, 1998.Google Scholar
  72. 72.
    Nelson S, Belknap SM, Carlson RW, Dale D, BeBoisblanc B, Farkas S, et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 178:1075, 1998.PubMedCrossRefGoogle Scholar
  73. 72b.
    Nelson S, Heyder AM, Stone J, et al. A ran-donited controlled trial of filgastrim for the treatment of hospitalized patients with multilobar pueumonia, J Infect Dis 182:970, 2000.PubMedCrossRefGoogle Scholar
  74. 73.
    Urban T, Lebeau B. Colony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies. Eur Resp J 13:1228, 1999.Google Scholar
  75. 74.
    Klimek JJ, Ajemian E, Tontecchio S, Gracewski J, Klemas B, Jiminez L. Community-acquired bacterial pneumonia requiring admission to hospital. Am J Infect Control 11:79, 1983.PubMedCrossRefGoogle Scholar
  76. 75.
    Aubertin J, Dabis F, Fleurett J, Bornstein N, Salamon R, Brottier E, et al. Prevalence of legionellosis among adults: a study of community-acquired pneumonia in France. Infection 15:328, 1987.PubMedCrossRefGoogle Scholar
  77. 76.
    Fang GD, Fine MJ, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multi-center study of 359 cases. Medicine 69:307, 1990.PubMedCrossRefGoogle Scholar
  78. 77.
    Lieberman D, Schlaeffer F, Boldur I, Horowitz S, Friedman MG, Leiononen M, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51:179, 1996.PubMedCrossRefGoogle Scholar
  79. 78.
    Tateda K, Matsumoto T, Ishii Y, Furuya N, Ohno A, Miyazaki S, et al. Serum cytokines in patients with Legionella pneumonia: relative predominance of Thl-type cytokines. Clin Diag Lab Immunol 5, 1998.Google Scholar
  80. 79.
    Friedman H, Yamamoto Y, Newton C, Klein T. Immunologic response and pathophysiology to Legionella infection. Semin Resp Infect 13:100, 1998.Google Scholar
  81. 80.
    Murray HW. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 108:608, 1989.Google Scholar
  82. 81.
    Nathan CF, Prendergast TJ, Wiebe ME, Stanley ER, Platzer E, Remold HG, et al. In vivo and in vitro activation of alveolar macrophages by recombinant interferon-γ. J Exp Med 160:600, 1984.PubMedCrossRefGoogle Scholar
  83. 82.
    Skerrett SJ, Martin TR. Intratracheal interferon- γ augments pulmonary defenses in experimental legionellosis. Crit Care Med 149:50, 1994.CrossRefGoogle Scholar
  84. 83.
    Jaffe R, Buhl R, Mastrangeli A, Holroyd KJ, Saltini C, Czerski D, et al. Organ specific cytokine therapy. J Clin Invest 88:297, 1991.PubMedCrossRefGoogle Scholar
  85. 84.
    Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349:1513, 1997.PubMedCrossRefGoogle Scholar
  86. 85.
    Remolina C, Khan AU, Santiago TV, et al. Positional hypoxemia in unilateral lung disease. N Engl J Med 304:523, 1981.PubMedCrossRefGoogle Scholar
  87. 86.
    Carlon GC, Ray CR, Klein R, et al. Criteria for selective positive end-expiratory pressure and independent synchronized ventilation of each lung. Chest 74:501, 1978.PubMedCrossRefGoogle Scholar
  88. 87.
    Hillman KM, Barber JD. Asynchronous independent lung ventilation (AILV). Crit Care Med 8:390, 1980.PubMedCrossRefGoogle Scholar
  89. 88.
    Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 282:77, 1999.CrossRefGoogle Scholar
  90. 89.
    Zapol WM, Snider MT, Hill JD. Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 242:2193, 1979.PubMedCrossRefGoogle Scholar
  91. 90.
    ECMO Registry of the Extracorporeal Life Support Organization (ELSO). ECMO Quarterly Report (January) 1997.Google Scholar
  92. 91.
    Green TP, Timmons OD, Fackler JC, Moler FW, Thompson AE, Sweeney MF, et al. The impact of extracorporeal membrane oxygenation on survival in pediatric patients with acute respiratory failure. Crit Care Med 24:323, 1996.PubMedCrossRefGoogle Scholar
  93. 92.
    Masiakos PT, Islam S, Doody DP, Schnitzer JJ, Ryan DP. Extracorporeal membrane oxygenation for nonneonatal acute respiratory failure. Arch Surg 134:375, 1999.PubMedCrossRefGoogle Scholar
  94. 93.
    Meyer TA, Warner BW. Extracorporeal life support for the treatment of viral pneumonia: collective experience from the ELSO registry. J Pediatr Surg 32:232, 1997.PubMedCrossRefGoogle Scholar
  95. 94.
    Kolla S, Awad SS, Rich PB, Schreiner RJ, Hirschl RB, Bartlett RH. Extracorporeal life support for 100 adult patients with severe respiratory failure. Ann Surg 226:544, 1997.PubMedCrossRefGoogle Scholar
  96. 95.
    Ichiba S, Jenkins DR, Peek GJ, Brennan KJ, Killer HM, Sosnowski A, et al. Severe acute respiratory failure due to legionella pneumonia treated with extracorporeal membrane oxygenation. Clin Infect Dis 28:686, 1999.PubMedCrossRefGoogle Scholar
  97. 96.
    Nakajima H, Kutsuwada T, Ohdaira T, Saito A, Satoh K, Igarashi K, et al. Extracorporeal membrane oxygenation for acute respiratory failure induced by Legionella pneumophile. Nihon Kyobu Shikkan Gakkai Zasshi 35:1363, 1997.PubMedGoogle Scholar
  98. 97.
    Codispoti M, Sanger K, Mankad PS. Successful extracorporeal membrane oxygenation (ECMO) support for fulminant community-acquired pneumococcal pneumonia. Thorax 50:1317, 1995.PubMedCrossRefGoogle Scholar
  99. 98.
    Lee WA, Kolla S, Schreiner RJ, Hirschl RB, Bartlett RH. Prolonged extracorporeal life support for varicella pneumonia. Crit Care Med 25:997, 1997.Google Scholar
  100. 99.
    Crowley MR, Katz RW, Kessler R, Simpson SQ, Levy H, Hallin GW, et al. Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med 26:409, 1998.PubMedCrossRefGoogle Scholar
  101. 100.
    Dickson EW, Heard SO, Chu B, Fraire A, Brueggemann AB, Doern GV. Partial liquid ventilation with perfluorocarbon in the treatment of rats with lethal pneumococcal pneumonia. Anesthesiology 88:218, 1998.PubMedCrossRefGoogle Scholar
  102. 101.
    Quezado ZM, Natanson C, Karzai W, Danner RL, Koev CA, Fitz Y, et al. Cardiopulmonary effects of inhaled nitric oxide in normal dogs and during E. coli pneumonia and sepsis. J Appl Physiol 84:107, 1998.PubMedCrossRefGoogle Scholar
  103. 102.
    Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 343:1199, 1994.PubMedCrossRefGoogle Scholar
  104. 103.
    Hoehn T, Huebner J, Paboura E, Krause M, Leititis JU. Effect of therapeutic concentrations of nitric oxide on bacterial growth in vitro. Crit Care Med 26:1857, 1998.PubMedCrossRefGoogle Scholar
  105. 104.
    Chollet-Martin S, Gatecel C, Kermarrec N, Gougerot-Pocidalo M, Payen DM. Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 153:985, 1996.PubMedCrossRefGoogle Scholar
  106. 105.
    Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aeroslized prostacyclin in severe pneumonia. Am J Respir Crit Care Med 151:724, 1995.PubMedGoogle Scholar
  107. 106.
    Confalonieri M, Potena A, Carbone G, Delia Porta R, Tolley EA, Meduri GU. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 160:1585, 1999.PubMedCrossRefGoogle Scholar
  108. 107.
    Joshi N, Localio AR, Hamory BH. A predictive risk index for nosocomial pneumonia in the intensive care unit. Am J Med 93:135, 1992.PubMedCrossRefGoogle Scholar
  109. 108.
    Olivier KN, Bennett WD, Hohneker KW, Zeman KL, Edwards LJ, Boucher RC, et al. Acute safety and effects on mucociliary clearance of aerosolized uridine 5-triphospate +/– amiloride in normal human adults. Am J Respir Crit Care Med 154:217, 1996.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Grant W. Waterer
  • Richard G. Wunderink

There are no affiliations available

Personalised recommendations